Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Clear those 4's out and we are green on the day.
I'm a buyer at these levels!!!!!
L2 looks thin, and i hear this is going to make some noise this week.
.0073 are up
looking good
Bid .007 with 1 and ask 0071 with 2
only 200K of my 800K filled
My 800000 is not getting filled!
just put in a 900,000 for .0086
Just bought 279400 and 20600 at .0085
I will buy your shares ANG HANK
Try to buy under 35- WON'T HAPPEN
I love how they try to scare us by walking it down with 150-500 buys and sells then swooping up the panic ones. Just a matter a time before this goes back up.
I agree with you. In the past I have lost ALOT of money on penny stocks. Sticking with your own rules seems to work. Once you deviate from them, this is when you loose.
When it comes down to it - pennies are meant for day trading. If you believe you have a long term winner, your wrong. one in a million you find a good one that has true PR's and balance sheets-if they have ever had one.
Broke Azz, could you fill me/us in on your strict trading rules. I am very interested in how you view penny stocks.
Guys, I HAVE ONE QUESTION??? So I have done some research on this company and I last thing I want to do is sound like MR. Negativity! But......I was reading their website (http://www.evermediabiometrics.com) under "Patents" and the two patents they list are valid (U.S. Patent No. 7,302,087 and U.S. Patent No. 7,298,874). However, both patents have Cho; Seong-Won (Seoul, KR) as the inventor and an assignee of Senga Advisors, LLC (Boston, MA). Boston makes sense, as the CEO is a grad of Boston U.
However, the website says they have two US patents pending. I can find pending patents under the inventor Cho; Seong-Won. Does any one know who this dude is? This IRIS tech. could be huge, but is this piggy-backing off of someone or some other company?
NEWS! Form 8K is out and it looks good!
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6665142
NEWS!!!! FAA
Mundus Group, Inc. Announces that Its Subsidiary, AirStar International and Its Technology Partner, Flint Hills Solutions, Have Been Successful in Obtaining a Certificate of Authorization from the Federal Aviation Administration for Operations in the National Air Space (NAS) at Crisis City, Kansas
4:00 am ET 01/20/2010 - PR Newswire
LOS ANGELES, Jan. 20 /PRNewswire-FirstCall/ -- The Federal Aviation Administration has issued a Certificate of Authorization (COA) for the FH 500 UAV which is operated and built by Flint Hills Solutions, LLC. of Augusta, KS. AirStar is a major contributor to the FH 500 UAV production as the FH 500 is built on one of AirStar's gas helicopter platforms. The COA allows for safe operations at Crisis City, an emergency response training area in the NAS located in Kansas.
Flint Hills Solutions uses AirStar International's state of the art gas RC helicopters as the platform to host FHS's UAS technology for autonomous navigation. In addition to integrating an autopilot system onto AirStar's helicopters, fully stabilized gimbal cameras and video transmitters are also integrated allowing for remote live video feeds to emergency responders. The ability to fly the FH 500 UAV over Crisis City allows it to be integrated into extensive training conducted there for search and rescue operations. Training includes hovering over simulated disaster sites such as rubble piles and transmitting geo-referenced video to the emergency response team on the ground. Roger Powers, founder and CEO of Flint Hills Solutions said, "The COA is a huge step in opening up the market for the utilization of AirStar platforms and FHSs UAVs in Emergency Response scenarios. The fact that the FAA has granted us this COA is proof that AirStar's helicopters are a solid addition to our autonomous UAV systems by providing a reliable, safe, and long endurance platform for our systems." Having successfully received a COA, Flint Hills Solutions and expects to be able to obtain an Emergency COA allowing them to fly in different locations across the state or U.S., including tornado disaster sites within a matter of hours.
New Out
Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
11:30 am ET 11/24/2009 - PR Newswire
BELGRADE, Serbia, Nov. 24 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, is providing this brief update to its followers and shareholders. HTDS management continues due diligence with the EU stem cell company and merger discussions. This relates to the previous announcement on or about Oct 29, 2009 which the company made. http://www.pinksheets.com/pink/quote/quote.jsp?symbol=HTDS#getNews.
HTDS and Slavica Biochem are also discussing on expanding the research topics to include other applications from the field of regenerative medicine. The newly discussed project would be dealing with a method for treatment of damaged articular cartilage - the autologous implantation of in vitro cultivated chondrocytes (the cells which form the cartilage). This new technique is one of the most important orthopaedic achievements of this century. As aforementioned the research team from Slavica BioChem www.slavicabiochem.com is considering a merger with the bio company from one of the EU countries where this technology is already being deployed. The HTDS management does not wish to disturb its current share structure in the merger discussions. One alternative solution currently being explored by the management is to license this technology and to use HTDS own cash resources and low labour costs in Serbia to launch both enterprises in Serbia. The company would generate revenues with the export throughout western Europe.
Marker Reports and similar research studies indicate that stem cell and regenerative medicine is a ~$25 billion dollar new industry. (2008 data) (source) Jain PharmaBiotech's "Cell Therapy" market report: (1) related to the commercialization of cell therapies, regenerative medicine products, (market, and commercial overview data.) http://www.docstoc.com/docs/1025099/Cell-Therapy-Business-Market-Summary-(July-2008) (unauthorized link)
A medical research report of the autologous chondrocytes project is filed with Pink Sheets www.pinksheets.com under the "Filings Tab".
HTDS operates two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc.www.mellowhope.com. Slaivca's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases